Cerevel Therapeutics Holdings Inc

General ticker "CERE" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $7.7B

Cerevel Therapeutics Holdings Inc follows the US Stock Market performance with the rate: 48.0%.

Estimated limits based on current volatility of 0.3%: low 44.72$, high 44.99$

Factors to consider:

  • Earnings expected soon, date: 2024-08-07
  • Earnings for 15 months up through Q1 (+1 year) exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2022-12-31 to 2024-12-30

  • 2022-12-31 to 2023-12-31 estimated range: [13.07$, 32.68$]
  • 2023-12-31 to 2024-12-30 estimated range: [8.53$, 23.35$]

Financial Metrics affecting the CERE estimates:

  • Negative: Non-GAAP EPS of -2.32 <= 0.08
  • Negative: Operating Income to Revenue ratio of -1.00 <= 0.01
  • Negative: Operating Cash Flow per share of -1.94 <= 0.20
  • Negative: negative Net Income
  • Negative: 0 < Interest Expense per share of 0.06

Similar symbols

Short-term CERE quotes

Long-term CERE plot with estimates

Financial data

YTD 2020-12-31 2021-12-31 2022-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $149.12MM $220.10MM $367.85MM
Operating Income $-149.12MM $-220.10MM $-367.85MM
Non-Operating Income $-3.05MM $-5.24MM $16.50MM
Interest Expense $0.00MM $0.00MM $9.62MM
R&D Expense $103.30MM $161.85MM $280.26MM
Income(Loss) $-152.17MM $-225.33MM $-351.35MM
Taxes $-0.02MM $0.00MM $0.16MM
Profit(Loss) $-152.14MM $-225.33MM $-351.51MM
Stockholders Equity $384.52MM $578.73MM $521.24MM
Assets $445.27MM $688.92MM $1,017.82MM
Operating Cash Flow $-117.80MM $-178.55MM $-293.19MM
Investing Cash Flow $-18.89MM $-435.66MM $-388.83MM
Financing Cash Flow $440.83MM $423.60MM $623.19MM
Earnings Per Share* $-2.07 $-1.63 $-2.32

* EPS are Split Adjusted, recent splits may be reflected with a delay.